The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.
 
Toshiaki Iwase
No Relationships to Disclose
 
Lajos Pusztai
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Athenex; Bristol-Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - NanoString Technologies
 
Kim Blenman
No Relationships to Disclose
 
Xiaotong Li
No Relationships to Disclose
 
Robert Seitz
Employment - OncoCyte
 
Tyler J Nielsen
Employment - OncoCyte
 
Brock L Schweitzer
Employment - OncoCyte
 
David Richard Hout
Employment - Insight Genetics; OncoCyte
Leadership - Insight Genetics
Stock and Other Ownership Interests - Insight Genetics
Patents, Royalties, Other Intellectual Property - I hold patents with Insight Genetics, but no royalties.
Travel, Accommodations, Expenses - Insight Genetics
 
Dan B Bailey
Employment - OncoCyte
 
Xiang Zhang
No Relationships to Disclose
 
Yichao Shen
No Relationships to Disclose
 
Naoto T. Ueno
Honoraria - Amgen; Chugai/Roche; Eisai; Henry Stewart Talks; Kyowa Hakko Kirin; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Immunomedics; Samsung Bioepis
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Puma Biotechnology; Sysmex
Travel, Accommodations, Expenses - Kyowa Hakko Kirin